Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry

Blood

Volumn 95, Issue 6, 2000, Pages 1883-1890

  Brümmendorf, Tim H ^b   Holyoake, Tessa L ^b   Rufer, Nathalie ^b   Barnett, Michael J ^b   Schulzer, Michael ^b   Eaves, Connie J ^b   Eaves, Allen C ^b   Lansdorp, Peter M ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER CELL; CELL DIVISION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; FLOW CYTOMETRY; GENETIC DISORDER; HUMAN; HUMAN CELL; LEUKOCYTE; MAJOR CLINICAL STUDY; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; STEM CELL; TELOMERE;

EID: 0343750701     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.6.1883     Document Type: Article

References (66)

1. Raskind WH, Fialkow PJ. The use of cell markers in the study of human hematopoietic neoplasia. Adv Cancer Res. 1987;49:127.
2. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85.
3. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290.
4. Groffen J, Stephenson JR, Heisterkamp N, De Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93.
5. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell. 1986;47:277.
6. Jonas D, Lubbert M, Kawasaki ES, et al. Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia. Blood 1992;79:1017.
7. Haferlach T, Winkemann M, Nickenig C, et al. Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques. Br J Haematol. 1997;97:99.
8. Coulombel L, Kalousek DK, Eaves CJ, Gupta CM, Eaves AC. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med. 1983;308:1493.
9. Udomsakdi C, Eaves CJ, Swolin B, Reid DS, Barnett MJ, Eaves AC. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci U S A. 1992;89:6192.
10. Wang JCY, Lapidot T, Cashman JD, et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood. 1998;91:2406.
11. + cells. Blood. 1998;91:630.
12. Dazzi F, Capelli D, Hasserjian R, et al. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology. Blood. 1998;92:1390.
13. Eaves AC, Barnett MJ, Ponchio L, Cashman JD, Petzer A, Eaves CJ. Differences between normal and CML stem cells: potential targets for clinical exploitation. Stem Cells. 1998;16(suppl 1):77.
14. Eaves CJ, Eaves AC. Cell culture studies in CML. In: Hinton K, ed. Bailliere's Clinical Haematology. London: Bailliere Tindall/WB Saunders; 1987: 931.
15. + cells. Br J Haematol. 1998;102:759.
16. Petzer AL, Eaves CJ, Barnett MJ, Eaves AC. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood. 1997;90:64.
17. Allouche M, Bourinbaiar A, Georgoulias V, et al. T cell lineage involvement in lymphoid blast crisis of chronic myeloid leukemia. Blood 1985;66:1155.
18. Fermand JP, Sigaux F, Tsapis A, et al. T cell-derived blast crisis in chronic myelocytic leukemia. Leukemia. 1987;1:210.
19. Gramatzki M, Bartram CR, Muller D, Walter M, Titlelbach H, Kalden JR. Early T cell differentiated chronic myeloid leukemia blast crisis with rearrangement of the breakpoint cluster region but not of the T cell receptor beta chain genes. Blood. 1987;69:1082.
20. Schuh AC, Sutherland DR, Horstall W, et al. Chronic myeloid leukemia arising in a progenitor common to T cells and myeloid cells. Leukemia. 1990;4:631.
21. Blackburn EH. Structure and function of telomeres. Nature. 1991;350:569.
22. Greider CW. Telomere length regulation. Annu Rev Biochem. 1996;65:337.
23. Martens UM, Zijlmans JMJM, Poon SSS, et al. Short telomeres on human chromosome 17p. Nat Genet. 1998;18:76.
24. Olovnikov AM. A theory of marginotomy. J Theor Biol. 1973;41:181.
25. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345:458.
26. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutat Res. 1991;256:271.
27. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature. 1990;346:866.
28. Allsopp RC, Vaziri H, Patterson C. et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A. 1992;89: 10,114.
29. Blasco MA, Lee H-W, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 1997;91:25.
30. Lee H-W, Blasco MA, Gottlieb GJ, Horner JW III, Greider CW, DePinho RA. Essential role of mouse telomerase in highly proliferative organs. Nature. 1998;392:569.
31. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33: 787.
32. Weng N-P, Hathcock KS, Hodes RJ. Regulation of telomere length and telomerase in T and B cells: a mechanism for maintaining replicative potential. Immunity. 1998;9:151.
33. de Lange T. Telomere dynamics and genome instability in human cancer. In: Blackburn EH and Greider CW, eds. Telomeres. New York, NY: Cold Spring Harbor Laboratory Press; 1995:265.
34. Lansdorp PM. Lessons from mice without telomerase. J Cell Biol. 1997;139:309.
35. Rudolph KL, Chang S, Lee H-W, et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell. 1999;96:701.
36. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279:349.
37. Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol. 1998;8:279.
38. Beattie TL, Zhou W, Robinson MO, Harrington L. Reconstitution of human telomerase activity in vitro. Curr Biol. 1998;8:177.
39. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci U S A. 1994;91:9857.
40. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci U S A. 1995;92:9082.
41. Chiu C-P, Dragowska W, Kim NW, et al. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells. 1996;14:239.
42. Yui J, Chiu C-P, Lansdorp PM. Telomerase activity in candidate stem cells from fetal liver and adult bone marrow. Blood. 1998;91:3255.
43. Lansdorp PM, Dragowska W, Mayani H. Ontogeny-related changes in proliferative potential of human hematopoietic cells. J Exp Med. 1993; 178:787.
44. Lansdorp PM. Developmental changes in the function of hematopoietic stem cells. Exp Hematol. 1995;23:187.
45. Lansdorp PM. Telomere length and proliferation potential of hematopoietic stem cells. J Cell Sci. 1995:108:1.
46. Wynn RF, Cross MA, Hatton C, et al. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet. 1998;351: 178.
47. Notaro R, Cimmino A, Tabarini D. Rotoli B, Luzzatto L. In vivo telomere dynamics of human hematopoietic stem cells. Proc Natl Acad Sci U S A. 1997;94:13,782.
48. Boultwood J, Fidler C, Shepherd P, et al. Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia. Am J Hematol. 1999;61:5.
49. Ohyashiki K, Ohyashiki JH, Iwama H, Hayashi S, Shay JW, Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia. 1997;11: 190.
50. Iwama H, Ohyashiki K, Ohyashiki JH, et al. The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myeloid leukemia. Cancer. 1997;79:1552.
51. Slagboom PE, Droog S, Boomsma DI. Genetic determination of telomere size in humans: a twin study of three age groups. Am J Hum Genet. 1994;55:876.
52. Rufer N, Brummendorf TH, Kolvraa S, et al. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med. 1999;190: 157.
53. Henderson LO, Marti GE, Gaigalas A, Hannon WH, Vogt RF Jr. Terminology and nomenclature for standardization in quantitative fluorescence cytometry. Cytometry. 1998;33:97.
54. Rufer N, Dragowska W, Thombury G, Roosnek E, Lansdorp PM. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat Biotechnol. 1998;16:743.
55. Hogge DE, Lansdorp PM, Reid D, Gerhard B, Eaves CJ. Enhanced detection, maintenance and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human Steel factor, interleukin-3 and granulocyte colony-stimulating factor. Blood. 1996;88:3765.
56. Fraser C, Eaves CJ, Kalousek DK. Fluorodeoxyuridine synchronization of hemopoietic colonies. Cancer Genet Cytogenet. 1987;24:1.
57. Barnett MJ, Eaves CJ, Phillips GL, et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood. 1994;84: 724.
58. Petzer AL, Eaves CJ, Lansdorp PM, Ponchio L, Barnett MJ, Eaves AC. Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood. 1996;88:2162.
59. Eaves C, Cashman J, Eaves A. Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia. Leuk Res. 1998;22:1085.
60. Ichimaru M, Ishimaru T, Mikami M, Yamada Y, Ohkita T. Incidence of leukemia in a fixed cohort of atomic bomb survivors and controls, Hiroshima and Nagasaki October 1950-December 1978. Technical Report RERF TR 13-81. Hiroshima, Radiation Effects Research Foundation, 1981.
61. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood. 1999;94:2056.
62. Eaves C, Udomsakdi C, Cashman J, Barnett M, Eaves A. The biology of normal and neoplastic stem cells in CML. Leuk Lymphoma. 1993; 11(suppl 1):245.
63. Bishop JM. Molecular themes in oncogenesis. Cell 1991;64:235.
64. Hande MP, Samper E, Lansdorp P, Blasco MA. Telomere length dynamics and chromosomal instability in cells derived from telomerase null mice. J Cell Biol. 1999;144:589.
65. Wan TSK, Martens UM, Poon SSS, Tsao S-W, Chan LC, Lansdorp PM. Absence or low number of telomere repeats at junctions of dicentric chromosomes. Genes Chromosomes Cancer. 1999; 24:83.
66. Zhu J, Wang H, Bishop JM, Blackburn EH. Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc Natl Acad Sci U S A. 1999;96:3723.